Study of GNX102 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
GNX-001 is an open-label, phase 1, multicenter, dose-escalation and expansion study of GNX102
infused every 21 days. Approximately 30 patients may be enrolled in the dose escalation
portion of this study. Once the MTD or recommended phase 2 dose (RP2D) has been identified,
up to 15 additional patients may be enrolled in one or two expansion cohort(s) at one or two
dose levels recommended by the Safety Review Committee) to confirm the safety profile of the
RP2D and provide additional information on anti-tumor activity.
Patients with adeno- or epithelial-cancers that have a likelihood of GNX102 targeted antigen
expression based on previous studies, including colorectal, hepatocellular, non-small cell
lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal,
prostate, and epithelial uterine cancers, can be screened for enrollment in the study.